David Fitts
About
David Fitts is a scholar working on Surgery, Genetics and Hematology.
According to data from OpenAlex, David Fitts has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 9 papers in Genetics and 7 papers in Hematology. Recurrent topics in David Fitts's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers), Nausea and vomiting management (7 papers) and Hemophilia Treatment and Research (7 papers). David Fitts is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers), Nausea and vomiting management (7 papers) and Hemophilia Treatment and Research (7 papers). David Fitts collaborates with scholars based in United States, United Kingdom and Netherlands. David Fitts's co-authors include Colin Broom, David M. Davidson, Oliver A. Cornely, Thomas Louie, Stuart Johnson, Steven P Gelone, Scott Chasan-Taber, Dale N. Gerding, Gordana Vlahovic and Osamu Takahashi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Infectious Diseases.
In The Last Decade
David Fitts
27 papers receiving 1.5k citations
Hit Papers
Peers
David Fitts
Katayoon Goodarzi United States
Yahya Büyükaşık Türkiye
Petra Glander Germany
Robert B. Geller United States
Jan Goßmann Germany
Johannes Waiser Germany
Filoména Conti France
Ki‐Seong Eom South Korea
Nicholas Bandarenko United States
Hee Seok Moon South Korea
Citations per year, relative to David Fitts David Fitts (= 1×)
peers
Katayoon Goodarzi
Countries citing papers authored by David Fitts
Since
Specialization
Citations
This map shows the geographic impact of David Fitts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Fitts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Fitts more than expected).
Fields of papers citing papers by David Fitts
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Fitts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Fitts. The network helps show where David Fitts may publish in the future.
Co-authorship network of co-authors of David Fitts
This figure shows the co-authorship network connecting the top 25 collaborators of David Fitts. A scholar is included among the top collaborators of David Fitts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Fitts. David Fitts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lodise, Thomas P., Sam Colman, Daniel S. Stein, et al.. (2020). Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. Open Forum Infectious Diseases. 7(5). ofaa145–ofaa145.
2.
Lodise, Thomas P., Sam Colman, Elizabeth Alexander, et al.. (2019). 676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2). Open Forum Infectious Diseases. 6(Supplement_2). S308–S309.
3.
Montgomery, Robert A., Babak J. Orandi, Lorraine C. Racusen, et al.. (2016). Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study. American Journal of Transplantation. 16(12). 3468–3478.
4.
Johnson, Stuart, Thomas Louie, Dale N. Gerding, et al.. (2014). Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials. Clinical Infectious Diseases. 59(3). 345–354.
5.
Ekman, Bertil, David Fitts, Claudio Marelli, et al.. (2014). European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocrine Disorders. 14(1). 40–40.
6.
Miller, Dave P., et al.. (2014). Relationship Between Angioedema Attacks and Health-Related Quality Of Life Outcomes In Patients With Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 133(2). AB33–AB33.
7.
Nilsson, A. G., Claudio Marelli, David Fitts, et al.. (2014). Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. European Journal of Endocrinology. 171(3). 369–377.
8.
Quinkler, Marcus, Bertil Ekman, David Fitts, et al.. (2014). Detection of high rate of intercurrent illnesses and adrenal crisis in patients with adrenal insufficiency by using a patient's diary. Endocrine Abstracts.
9.
Baker, James, Timothy Craig, Marc A. Riedl, et al.. (2013). Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy and Asthma Proceedings. 34(2). 162–169.
10.
Bernstein, Jonathan A., Michael Manning, Henry Li, et al.. (2013). Escalating Doses of C1 Esterase Inhibitor (CINRYZE) for Prophylaxis in Patients With Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 2(1). 77–84.e1.
11.
Lumry, William R., Michael Manning, David Hurewitz, et al.. (2013). Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C1-Inhibitor Deficiency in Children. The Journal of Pediatrics. 162(5). 1017–1022.e2.
12.
Fitts, David, et al.. (2013). European Adrenal Insufficiency Registry: a comparative observational study of glucocorticoid replacement therapy. Endocrine Abstracts.
13.
Grant, J. A., Martha V. White, H. Henry Li, et al.. (2012). Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy and Asthma Proceedings. 33(4). 348–353.
14.
Riedl, Marc A., David Hurewitz, Robyn J. Levy, et al.. (2011). Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Annals of Allergy Asthma & Immunology. 108(1). 49–53.
15.
Gralla, Richard J., et al.. (1998). Efficacy of Intravenous Granisetron to Control Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy. Cancer Investigation. 16(2). 87–93.
16.
Perez, Edith A., Rudolph M. Navari, Henry G. Kaplan, et al.. (1997). Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Supportive Care in Cancer. 5(1). 31–37.
17.
Ettinger, David S., et al.. (1996). A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer. 78(1). 144–151.
18.
Navari, Rudolph M., David R. Gandara, Paul J. Hesketh, et al.. (1995). Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.. Journal of Clinical Oncology. 13(5). 1242–1248.
19.
Navari, Rudolph M., Henry G. Kaplan, Richard J. Gralla, et al.. (1994). Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.. Journal of Clinical Oncology. 12(10). 2204–2210.
20.
McMahon, F. Gilbert, Ramón Vargas, Jerome R. Ryan, & David Fitts. (1987). Nabumetone kinetics in the young and elderly. The American Journal of Medicine. 83(4). 92–95.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katayoon Goodarzi Breakdown of academic impact, for papers by Yahya Büyükaşık Breakdown of academic impact, for papers by Petra Glander Breakdown of academic impact, for papers by Robert B. Geller Breakdown of academic impact, for papers by Jan Goßmann Breakdown of academic impact, for papers by Johannes Waiser Breakdown of academic impact, for papers by Filoména Conti Breakdown of academic impact, for papers by Ki‐Seong Eom Breakdown of academic impact, for papers by Nicholas Bandarenko Breakdown of academic impact, for papers by Hee Seok Moon